Literature DB >> 7740944

Survival after surgery for spinal and extremity metastases. Prognostication in 241 patients.

H C Bauer1, R Wedin.   

Abstract

We assessed the survival after surgery in 153 patients with extremity metastases and 88 with spinal metastases. The survival rate for the whole series of 241 patients was 0.30 at 1 year, 0.15 at 2, and 0.08 at 3 years. The 1-year survival rate was the same for the extremity metastases group and the spinal group. Univariate analysis showed that 1-year survival was related to metastatic load, site of primary tumor, and presence of pathologic fracture. Multivariate regression analysis showed that pathologic fracture, visceral or brain metastases, and lung cancer were negative prognostic variables. Solitary skeletal metastases, breast and kidney cancer, myeloma, and lymphoma were positive variables. A prognostication model based on these variables stratified the patients into 3 groups with a 1-year survival ranging from 0.5 to 0.0. These prognostic variables can be used for differentiating the treatment of cancer patients with pathologic fracture or epidural compression.

Entities:  

Mesh:

Year:  1995        PMID: 7740944     DOI: 10.3109/17453679508995508

Source DB:  PubMed          Journal:  Acta Orthop Scand        ISSN: 0001-6470


  106 in total

1.  Metastatic anal sac adenocarcinoma in a dog presenting for acute paralysis.

Authors:  Brigitte A Brisson; Douglas P Whiteside; David L Holmberg
Journal:  Can Vet J       Date:  2004-08       Impact factor: 1.008

2.  [Surgical treatment of skeletal metastases].

Authors:  T Gösling; M Becker-Schiebe
Journal:  Unfallchirurg       Date:  2015-04       Impact factor: 1.000

3.  Treatment results of pathological fractures of the long bones: a retrospective analysis of 88 patients.

Authors:  Kambiz Sarahrudi; Katherina Hora; Thomas Heinz; Steven Millington; Vilmos Vécsei
Journal:  Int Orthop       Date:  2006-08-30       Impact factor: 3.075

4.  Survival, complications and outcome in 282 patients operated for neurological deficit due to thoracic or lumbar spinal metastases.

Authors:  Karl-Ake Jansson; Henrik C F Bauer
Journal:  Eur Spine J       Date:  2005-03-03       Impact factor: 3.134

5.  Can A Multivariate Model for Survival Estimation in Skeletal Metastases (PATHFx) Be Externally Validated Using Japanese Patients?

Authors:  Koichi Ogura; Tabu Gokita; Yusuke Shinoda; Hirotaka Kawano; Tatsuya Takagi; Keisuke Ae; Akira Kawai; Rikard Wedin; Jonathan A Forsberg
Journal:  Clin Orthop Relat Res       Date:  2017-05-30       Impact factor: 4.176

6.  Survival, local control, and health-related quality of life in patients with oligometastatic and polymetastatic spinal tumors: A multicenter, international study.

Authors:  Ori Barzilai; Anne L Versteeg; Arjun Sahgal; Laurence D Rhines; Mark H Bilsky; Daniel M Sciubba; James M Schuster; Michael H Weber; Peter Pal Varga; Stefano Boriani; Chetan Bettegowda; Michael G Fehlings; Yoshiya Yamada; Michelle J Clarke; Paul M Arnold; Ziya L Gokaslan; Charles G Fisher; Ilya Laufer
Journal:  Cancer       Date:  2018-11-29       Impact factor: 6.860

Review 7.  [Prognosis-adapted surgical management of bone metastases].

Authors:  S Utzschneider; P Weber; A Fottner; B Wegener; V Jansson; H R Dürr
Journal:  Orthopade       Date:  2009-04       Impact factor: 1.087

8.  [Surgical treatment of pathologic fractures of the humerus and femur].

Authors:  G Gruber; M Zacherl; A Leithner; C Giessauf; M Glehr; H Clar; R Windhager
Journal:  Orthopade       Date:  2009-04       Impact factor: 1.087

9.  Risk factors for survival of 106 surgically treated patients with symptomatic spinal epidural metastases.

Authors:  L Bollen; G C W de Ruiter; W Pondaag; M P Arts; M Fiocco; T J T Hazen; W C Peul; P D S Dijkstra
Journal:  Eur Spine J       Date:  2013-03-02       Impact factor: 3.134

10.  Minimally invasive treatment of pathological fractures of the humeral shaft.

Authors:  Onder Ofluoglu; Bulent Erol; Zerrin Ozgen; Muzaffer Yildiz
Journal:  Int Orthop       Date:  2008-04-03       Impact factor: 3.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.